Next, we investigated the effect of PLA2G4A inhibition on additional MLLr AML lines (Nomo-1 (MLL-AF9) and MV-4-11 (MLL-AF4)) as well as of unrelated AML lines (Kasumi-1 (RUNX1/AML1-RUNX1T1/ETO) and OCI-AML3 (NPM1c)). This evidence concerns the gene KMT2A and acute myeloid leukemia.